Metropolis Healthcare Ltd. · NSE:METROPOLIS
Metropolis Healthcare — Q1 FY2025 Earnings Presentation
25 slides from Metropolis Healthcare's earnings presentation, Aug 10, 2024
Slide 1: Intimation of Investor Presentation
Ref: MHL/Sec&Legal/2024-25/36 Date: August 10, 2024 To, BSE Limited National Stock Exchange of India Ltd Scrip Code: 542650 Scrip Symbol: METROPOLIS Dear Sir/ Madam, Sub: Intimation of Investor Presentation Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulatio
Slide 2: Q1FY25 Investor Presentation
METROPOLIS HEALTHCARE LIMITED Q1FY25 INVESTOR PRESENTATION
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Metropolis Healthcare Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 4: Content
Performance Highlights 1 Financial performance indicators Segment, Volume and other Operational KPIs 2 performance indicators Content Performance and Company Profit & Loss 3 Income Statement Updates Q1FY25 Metropolis 3.0 Metropolis 3.0 strategy including Strategy 4 network, digital, science and qual
Slide 5: Metropolis – Diagnostics that's trusted by doctors and patients alike
Metropolis – Diagnostics that’s trusted by doctors and patients alike OUR VISION 43+ years of To be a respected healthcare brand trusted by 12% CAGR credible clinicians, patients and stakeholders. Positively for impact the lives of patients in their most anxious last 8 years experience times and tur
Slide 6: Q1FY25 Performance Highlights
Q1FY25 Performance Highlights Revenue EBITDA PAT INR 313.4 Cr INR 78.2 Cr Rs. 38.1 Cr 13.1% YoY 21.2% YoY 31.3% YoY Margins growing faster than revenue growth indicating high operating leverage Consistently delivering on revenue growth, as per guidance EBITDA margin at 25% and PAT margin at 12.2%, b
Slide 7: Q1FY25 Key Performance Indicators
Q1FY25 Key Performance Indicators • Consistent patient & test Patient Volume B2C Revenue B2B Revenue volume growth 3.04 Mn INR 169 Cr INR 117 Cr 7% YoY 18% • TruHealth (Wellness & 12% Bundling) and Specialty – double engine firing TruHealth Specialty • B2C revenue growth Test Volume outperforming ov
Slide 8: Robust revenue on the back of consistent Patient & Test Volume growth
Robust revenue on the back of consistent Patient & Test Volume growth @ 7% & 10% respectively Patient Volume (in Mn) Test Volume (in Mn) 9.7% 6.3 5.7 6.9% Increase in test volume due to 2.84 3.04 increased test per patient, footfalls and network expansion Q1FY24 Q1FY25 Q1FY24 Q1FY25 Higher contribut
Slide 9: Strong B2C revenue growth @ 18.4% YoY
Strong B2C revenue growth @ 18.4% YoY B2C test volume grew by 9.2% & RPT by 9% Price Revision, Network +22% Expansion, TruHealth focus +300 +18% and operational rigor bps +31% driving growth across channels and markets Metropolis remains a preferred choice for B2C Contribution B2C Revenue(Mumbai) B2
Slide 10: B2B revenue growing by 12.4% YoY
B2B revenue growing by 12.4% YoY – double digit growth, second quarter in a row B2B test volume grew by 9% & RPT by 3% +24% Despite competition +18% intensity, we have been +12.4% able to deliver sustained +11% growth for our B2B business Higher B2B Engagement via +18% Partner portal, helpdesk and s
Slide 11: TruHealth Revenue grew @ 28% YoY
TruHealth Revenue grew @ 28% YoY • Margin accretive packages with average realizations of over Rs. 2,500 Growth • Upselling Bundled testing to Routine testing patients through scientifically crafted packages and profiles for various risk-category 28% patients across age segments • Omnichannel upsell
Slide 12: Speciality Revenue grew @ 14% YoY
Speciality Revenue grew @ 14% YoY • More than 3,000 specialty tests and uniquely crafted profiles Specialty across Gastroenterology, Nephrology, Neurology, Oncology, Growth Women & Child, Infectious and Chronic Diseases 14% • Focus on genomics - revenue from NGS/molecular genomics segment growing dr
Slide 13: Network Expansion - on course to add labs & service centers by FY25
Network Expansion - on course to add 90 labs & 2000 service centers by FY25 Laboratory Network Service Network 199 204 4,150 4,216 Rationalization Period 175 3,675 805 816 161 124 125 +79 2,731 2,555 3,134 704 754 +1,661 119 2,336 598 labs 575 498 2,929 centres 2,914 2,594 2,105 1,873 1,806 Rural 1,
Slide 14: Diversified Revenue contribution across Geographies
Diversified Revenue contribution across Geographies Revenue Contribution Revenue Growth (MHL Categorisation) Focus 11% By Cities 27% Focus Seeding Seeding 3% 57% Others 16% Others 26% Presence in Revenue Contribution Revenue Growth 650+ towns Network expansion leading to 25% T1 10% By City Tier Tier
Slide 15: Q1 FY25 Consolidated Profit & Loss Statement
Q1 FY25 Consolidated Profit & Loss Statement Profit & Loss Statement (INR. Crs.) Q1FY25 Q1FY24 Y-o-Y Revenue from Operations 313.4 277.1 13.1% Cost of Operations 232.8 210.1 EBIDTA (before CSR and ESOP) 80.5 67.0 20.2% EBIDTA (before CSR and ESOP) Margin 25.7% 24.2% +150 bps ESOP & CSR Cost 2.3 2.5
Slide 16: Metropolis 3.0
Metropolis 3.0 METROPOLIS
Slide 17: Key Pillars of Metropolis 3.0 Strategy
Key Pillars of Metropolis 3.0 Strategy – poised to grow further 1 Strengthening the Core Expand market share in core and newer geographies with a focus on specialized and wellness testing, while creating a differentiated brand and empowering with AI and digitization Expand to Adjacencies while Forgi
Slide 18: Driving business growth through Digital Transformation
Driving business growth through Digital Transformation Metropolis is a unique Healthcare Company equipped with SalesForce CDP, Marketing Cloud, Service Cloud, Sales Cloud, Community Cloud Accurate Efficient Efficient Patient 360-Degree Opportunity Case Relationship Reporting & Cross Channel Enhanced
Slide 19: Scientifically driven with strong focus on quality, research and academics
Scientifically driven with strong focus on quality, research and academics Scientific Expansion in Test Menu • New test launched across Oncology, Nephrology, Gynecology and 102 New Tests added in FY24 Infectious and Chronic disease segment • Focus on NGS/molecular genomics segment growing driven by
Slide 20: Metropolis ESG Goals
Metropolis ESG’ Goals • Carbon Neutrality by 2043 Emission Goals for a Greener Tomorrow • 45% reduction in emissions intensity by 2030 Well identified ESG Focus Areas and assessments created as per the materiality matrix based on the GRI, SASB and SDG Frameworks. Our first Business Responsibility Su
Slide 21: Key ESG Plans 2024-25
Key ESG Plans 2024-25 Emissions & Water & Waste Employee Risk Management Patient Privacy and Energy Management Recruitment, Electronic Health Development and Records Retention • Achieve 5% reduction in • Career 2.0 Campaign to increase • Annual assessments of Risk • 100% training on information • Ac
Slide 22: CSR at Metropolis – creating a positive impact
CSR at Metropolis – creating a positive impact Preventive healthcare DSEU* (Delhi Skills MedEngage Too Shy to Ask(TSTA) Entrepreneurial Project University) • Integrating all UG and PG • TSTA Rural focusing on adolescent • 1000 TB patients to receive programs including reproductive and sexual health,
Slide 23: Strong Leadership Team
Strong Leadership Team Dr. Sushil Shah Ameera Shah Surendran Chemmenkotil Chairman Emeritus Executive Chairperson Chief Executive Officer Dynamic Leadership Team for Next Level of Growth Dr. Nilesh Shah Rakesh Agarwal Kannan Alangadan Dr. Kirti Kazi Ishita Medhekar President - Internal Assurance Chi
Slide 24: Recent Awards and Accolades
Recent Awards and Accolades Gold Award - Diagnostic Chain of the Year and Bronze Award - Best CSR Practice in Apr’24 Healthcare at the FE Healthcare Excellence Awards 2024 CSR Program MedEngage - Winner at the 3rd edition of the NATHealth Impact Awards Mar’24 2024 in the CSR category International B
Slide 25: For further information, please contact
For further information, please contact: Company : Investor Relations Advisors : Metropolis Healthcare Ltd. Strategic Growth Advisors Pvt. Ltd. CIN – L73100MH2000PLC192798 CIN - U74140MH2010PTC204285 Mr. Rakesh Agarwal - CFO Mr. Shogun Jain / Mr. Sagar Shroff Email Id – rakesh.agarwal@metropolisindi
Metropolis Healthcare — Q1 FY2025 Earnings Presentation on 6ix